Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab Open-Label Extension in Atopic Dermatitis
NCT01949311Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Oct 2013
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 28
01
Overview
A Phase 3 trial of dupilumab in atopic dermatitis (AD), sponsored by Regeneron Pharmaceuticals. Started Oct 2013; status: completed.
02
Drugs
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT01949311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01949311.